Viyash Scientific (VIYASH.NS) Stock Price

Viyash Scientific Price

NSE·CLOSED
219.45
​
Market closed

Over the last 18 years Viyash Scientific grew revenue by 21.3% annually, reaching 15.51 B INR. Earnings per share have declined at 3.2% per year over the last 18 years. For Viyash Scientific, the net margin of 1.4% is down versus 7.0% a few years ago.

Viyash Scientific stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viyash Scientific business model & stock analysis

Viyash Scientific Ltd generates revenue through the manufacturing and sale of veterinary pharmaceuticals and specialty chemicals. The company offers finished dose formulations, active pharmaceutical ingredients (APIs), and analytical services to clients in the pharmaceutical, personal care, and nutraceutical industries. Its products target therapies such as anthelmintics, anti-protozoals, nutraceuticals, NSAIDs, anti-infectives, and dermatology solutions. The firm operates primarily through its pharmaceuticals segment, with subsidiaries Alivira Animal Health Limited and SeQuent Research Limited supporting its analytical and bioanalytical service offerings. The company's analytical services include method validation, stability testing, microbiology, and in-house method development, adhering to pharmacopoeia monographs and customer-specific requirements. These services are provided to API, pharmaceutical, personal care, and nutraceutical companies seeking regulatory compliance and quality assurance. The firm's focus on targeted therapies and specialized services positions it to serve a niche market within the animal health sector. Viyash Scientific Ltd's revenue streams are derived from both product sales and service contracts. The pharmaceuticals segment, which includes APIs and finished formulations, represents a core business area, while analytical services form a complementary revenue source. The company leverages its subsidiaries to enhance its service capabilities, particularly in analytical and bioanalytical support for clients across multiple industries.

Frequently asked questions about Viyash Scientific

6 analysts currently rate the Viyash Scientific stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Viyash Scientific to generate revenue of 33.72 B INR and earnings per share of 11.57 INR.

Converted at the current exchange rate, the Viyash Scientific share trades at 2.07 EUR (219.45 INR).

The Viyash Scientific share (VIYASH.NS) is listed on 2 stock exchanges, including: NSE (Indien) (SEQUENT.NS).

The expected revenue of Viyash Scientific is 33.72 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Viyash Scientific is 2.97 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Viyash Scientific is currently 18.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Viyash Scientific stock.

The price-to-sales ratio (P/S) of Viyash Scientific is currently 1.67. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Viyash Scientific stock.

The Eulerpool Quality Score for Viyash Scientific is 4/10.

The ISIN of Viyash Scientific is INE807F01027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Viyash Scientific is VIYASH.NS. The ticker symbol is used to trade Viyash Scientific shares on the stock exchange.

Fair ValueTerminal
204.09 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
32.46 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website sequent.in
Country
Currency
INR
Initial public offering
Mar 10, 2016
ISIN
INE807F01027
Cusip
Y7670U126
Market capitalization
95.73 B INRLarge Cap
52-Week Range
PEG
13.13
P/E ratio
P/Ee 2026
32.27
P/Ee 2027
27.69
P/Ee 2028
18.64
P/Ee 2029
15.79
P/S
P/Se
1.67
EV/EBIT
99.18
P/B Ratio
13.59
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1.85 %
Last updated Nov 4, 2026, 4:23 AM

Viyash Scientific Peer Group

Viyash Scientific Ticker

BSE · SEQUENT.BONSE INDIA · SEQUENT.NS

Viyash Scientific FIGI

SEQ:IN · BBG000BHLQ53SEQ:IB · BBG000BHLQK6SEQ:IS · BBG000BHLRM2

All fundamentals and in-depth analysis of Viyash Scientific

Our stock analysis for Viyash Scientific stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Viyash Scientific. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.